Case series exploring hormonal sensitivity in prostate cancer patients harboring the germline African-ancestry HOXB13 X285K variant

Mayuko Kanayama; Emeline Colomba; Yusra Shao; Sarah M. Nielsen; Edward D. Esplin; Changxue Lu; William B. Isaacs; John C. Henegan; Elisabeth I. Heath; Jun Luo; Régine Marlin; Emmanuel S. Antonarakis

doi:10.1038/s41391-025-00994-5

Case series exploring hormonal sensitivity in prostate cancer patients harboring the germline African-ancestry HOXB13 X285K variant

Mayuko Kanayama
, Emeline Colomba
, Yusra Shao
, Sarah M. Nielsen
, Edward D. Esplin
, Changxue Lu
, William B. Isaacs
, John C. Henegan
, Elisabeth I. Heath
, Jun Luo
, Régine Marlin
, Emmanuel S. Antonarakis

Medicine - Hematology, Oncology, Transplant

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Background: Recently, a germline HOXB13 variant, X285K was identified as a risk factor for prostate cancer in men of African ancestry. While this variant is likely associated with more aggressive prostate cancer, there has not yet been an in-depth clinical description of individual patients carrying this variant and their response to systemic therapies. Methods: We studied six cases of germline X285K carriers with metastatic hormone-sensitive prostate cancer to characterize their hormonal sensitivity or resistance. Conclusions: Longitudinal outcome analysis indicates that patients carrying X285K generally show favorable responses to therapies targeting the androgen receptor (AR), a finding that requires confirmation.

Original language	English (US)
Pages (from-to)	633-637
Number of pages	5
Journal	Prostate Cancer and Prostatic Diseases
Volume	29
Issue number	3
DOIs	https://doi.org/10.1038/s41391-025-00994-5
State	Published - Sep 2026

Bibliographical note

Publisher Copyright:
© The Author(s), under exclusive licence to Springer Nature Limited 2025.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

PubMed: MeSH publication types

Journal Article

Publisher link

10.1038/s41391-025-00994-5

Find It

Find It at U of M Libraries

Cite this

Kanayama, M., Colomba, E., Shao, Y., Nielsen, S. M., Esplin, E. D., Lu, C., Isaacs, W. B., Henegan, J. C., Heath, E. I., Luo, J., Marlin, R., & Antonarakis, E. S. (2026). Case series exploring hormonal sensitivity in prostate cancer patients harboring the germline African-ancestry HOXB13 X285K variant. Prostate Cancer and Prostatic Diseases, 29(3), 633-637. https://doi.org/10.1038/s41391-025-00994-5

Kanayama, M, Colomba, E, Shao, Y, Nielsen, SM, Esplin, ED, Lu, C, Isaacs, WB, Henegan, JC, Heath, EI, Luo, J, Marlin, R & Antonarakis, ES 2026, 'Case series exploring hormonal sensitivity in prostate cancer patients harboring the germline African-ancestry HOXB13 X285K variant', Prostate Cancer and Prostatic Diseases, vol. 29, no. 3, pp. 633-637. https://doi.org/10.1038/s41391-025-00994-5

@article{cb69001b52ca4bc7a79379b233181654,

title = "Case series exploring hormonal sensitivity in prostate cancer patients harboring the germline African-ancestry HOXB13 X285K variant",

abstract = "Background: Recently, a germline HOXB13 variant, X285K was identified as a risk factor for prostate cancer in men of African ancestry. While this variant is likely associated with more aggressive prostate cancer, there has not yet been an in-depth clinical description of individual patients carrying this variant and their response to systemic therapies. Methods: We studied six cases of germline X285K carriers with metastatic hormone-sensitive prostate cancer to characterize their hormonal sensitivity or resistance. Conclusions: Longitudinal outcome analysis indicates that patients carrying X285K generally show favorable responses to therapies targeting the androgen receptor (AR), a finding that requires confirmation.",

author = "Mayuko Kanayama and Emeline Colomba and Yusra Shao and Nielsen, \{Sarah M.\} and Esplin, \{Edward D.\} and Changxue Lu and Isaacs, \{William B.\} and Henegan, \{John C.\} and Heath, \{Elisabeth I.\} and Jun Luo and R{\'e}gine Marlin and Antonarakis, \{Emmanuel S.\}",

note = "Publisher Copyright: {\textcopyright} The Author(s), under exclusive licence to Springer Nature Limited 2025.",

year = "2026",

month = sep,

doi = "10.1038/s41391-025-00994-5",

language = "English (US)",

volume = "29",

pages = "633--637",

journal = "Prostate Cancer and Prostatic Diseases",

issn = "1365-7852",

publisher = "Springer Nature",

number = "3",

}

TY - JOUR

T1 - Case series exploring hormonal sensitivity in prostate cancer patients harboring the germline African-ancestry HOXB13 X285K variant

AU - Kanayama, Mayuko

AU - Colomba, Emeline

AU - Shao, Yusra

AU - Nielsen, Sarah M.

AU - Esplin, Edward D.

AU - Lu, Changxue

AU - Isaacs, William B.

AU - Henegan, John C.

AU - Heath, Elisabeth I.

AU - Luo, Jun

AU - Marlin, Régine

AU - Antonarakis, Emmanuel S.

PY - 2026/9

Y1 - 2026/9

N2 - Background: Recently, a germline HOXB13 variant, X285K was identified as a risk factor for prostate cancer in men of African ancestry. While this variant is likely associated with more aggressive prostate cancer, there has not yet been an in-depth clinical description of individual patients carrying this variant and their response to systemic therapies. Methods: We studied six cases of germline X285K carriers with metastatic hormone-sensitive prostate cancer to characterize their hormonal sensitivity or resistance. Conclusions: Longitudinal outcome analysis indicates that patients carrying X285K generally show favorable responses to therapies targeting the androgen receptor (AR), a finding that requires confirmation.

AB - Background: Recently, a germline HOXB13 variant, X285K was identified as a risk factor for prostate cancer in men of African ancestry. While this variant is likely associated with more aggressive prostate cancer, there has not yet been an in-depth clinical description of individual patients carrying this variant and their response to systemic therapies. Methods: We studied six cases of germline X285K carriers with metastatic hormone-sensitive prostate cancer to characterize their hormonal sensitivity or resistance. Conclusions: Longitudinal outcome analysis indicates that patients carrying X285K generally show favorable responses to therapies targeting the androgen receptor (AR), a finding that requires confirmation.

UR - https://www.scopus.com/pages/publications/105008478484

UR - https://www.scopus.com/pages/publications/105008478484#tab=citedBy

U2 - 10.1038/s41391-025-00994-5

DO - 10.1038/s41391-025-00994-5

M3 - Article

C2 - 40542273

AN - SCOPUS:105008478484

SN - 1365-7852

VL - 29

SP - 633

EP - 637

JO - Prostate Cancer and Prostatic Diseases

JF - Prostate Cancer and Prostatic Diseases

IS - 3

ER -

Case series exploring hormonal sensitivity in prostate cancer patients harboring the germline African-ancestry HOXB13 X285K variant

Abstract

Bibliographical note

UN SDGs

PubMed: MeSH publication types

Publisher link

Find It

Other files and links

Fingerprint

Cite this